Here, we tested the effectivity of the strongly anionic derivative of ibrutinib, ibrutinib-Cy 3.5 to form an αCD33-mAB-P/P nanoparticle that can be safely applied to target the CD33 expressing AML cell line OCI-AML2. Here, CD33 is linked to acute myeloid leukemia.